Abstract: A protective insert (10) operatively attachable to an inner, body-facing layer of a garment. The protective insert generally comprises, a first, operatively inner layer (12) comprising a moisture-wicking, odour resistance, fluid absorbent fibre with or without a waterproof laminate-film; and a second, operatively outer layer (14) comprising a breathable, odour resistant, water repellent fibre to further prevent fluid passage through the garment; wherein the operatively inner layer faces the body of a user while the operatively outer layer faces away from the body of a user, in use.

Abstract: A product for mitigating the ill-effects of post-coital discharge, post-medical-procedure discharge, and post-urination discharge in men. A sleeve-like pouch includes an inside and an outside, with a top layer disposed on the inside of the sleeve-like pouch, and a bottom layer disposed on the outside of the sleeve-like pouch. An absorbent layer is disposed between the top layer and bottom layer. The sleeve-like pouch is configured to be slid onto and securely surround a male appendage.

Abstract: In one aspect, a combinatorial drug delivery device is provided for delivering a predetermined selection of drug components. The device includes a plurality of modules, each including: a body having an interior volume; a spike plate movably disposed in the interior volume, the spike plate having a protruding cannula and first and second ports. The device also includes a base tray which includes: a framework defining a plurality of wells, each of the wells formed to insertingly receive one of the modules; for each of the wells, first and second inlet ports formed to interface with the first and second ports of the module being received in the respective well; passageways to connect certain wells with adjacent wells to permit fluid flow therebetween. For each of the wells, the spike plate of the respective module being maintained in a stationary position with the module being inserted into the well.

Abstract: Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.

Abstract: Methods and apparatuses are disclosed relating to the creation and use of bespoke wound fillers and other wound treatment apparatuses. Some embodiments provide for the creation of bespoke wound fillers based on characteristics of a wound. Certain embodiments also include the use of bespoke wound fillers in combination with negative pressure to treat a wound.

Abstract: Disclosed are a compound represented by the general Formula (I), or a stereisomer, tautomer, derivative, prodrug or pharmaceutically acceptable salt thereof, and a method for preparing the compound and use of the compound in manufacture of a medicament for treating a neuropathic pain and/or neuropathic pain syndrome or a medicament for combating an inflammation: wherein R1 is selected from hydrogen, halogen, alkyl, cyano and haloalkyl, R2 and R3 are independently selected from hydrogen, halogen, alkyl, haloalkyl and nitro, and R1, R2 and R3 are not hydrogen at the same time; furthermore, when either R2 or R3 is nitro or halogen, the other two of R1, R2 and R3 are not hydrogen at the same time. The compound has good effects in treating a neuropathic pain and/or neuropathic pain syndrome and good effects in combating an inflammation, and has not side effects such as addiction.

Abstract: The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)

Abstract: A TNIK and/or MAP4K4 kinase inhibitor can include: Formula A, derivative, prodrug, salt, stereoisomer, tautomer polymorph, or solvate thereof, or having chirality at any chiral center, wherein: ring 1 is an aromatic ring with or without hetero atoms; ring 2 is a hetero aromatic ring; ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring; ring 4 is an aromatic ring with or without hetero atoms; Y is a bond or a linker; Y1 is a linker; each n is independently 0, 1, or 2; each o is independently 0, 1, 2, 3, 4, or 5; each R1, R6, R11, and R12 is independently a substituent; and RA is a ring structure, straight aliphatics, or branched aliphatics, which can be substituted or unsubstituted, any with or without hetero atoms.

Abstract: An absorbent article, preferably a disposable absorbent article such as a diaper, is disclosed having an absorbent core which imparts increased wearing comfort to the article and makes it thin and dry. The absorbent core useful for an absorbent article comprises a substrate layer, a discontinuous layer of absorbent material, and a layer of thermoplastic material. A second surface of the discontinuous layer of absorbent material is in at least partial contact with a first surface of the substrate layer. Portions of a second surface of the layer of thermoplastic material are in direct contact with the first surface of the substrate layer and portions of said second surface of the layer of thermoplastic material are in direct contact with a first surface of the discontinuous layer of absorbent material. A process for providing a storage layer for an absorbent core useful in an absorbent article is further disclosed.

Abstract: Disclosed herein are improved dispensing devices for facilitating application of eye drops that are ergonomic, promote improved patient adherence, and eliminate the need for extraneous gadgets or facilitating devices that may add additional expense to users. A dispensing device can include a container body for storing drops and a nozzle coupled to the body for dispensing the drops. The device can include one or more channels defined on a surface of the container body and configured to couple, or otherwise mount or abut, to an anatomical structure of a user (such as, for example, a user's nose bridge or eyebrow ridge). The device can also include one or more grip areas defined on the container body and configured to allow a user to generally hold the device and to apply force thereto to dispense drops from the device.

Abstract: Disclosed is a method for preparing 2-indolinospirone compound and intermediate thereof, specifically disclosed is a method for preparing a compound of formula 5. The method is relatively simple and has high stereoselectivity and yield.

Abstract: Exemplary wearable articles including regions with differing visual patterns are disclosed. In one embodiment, an article may comprise an elasticated front chassis region and an elasticated front waistband region, a rear region, a crotch region, and an absorbent body disposed at least partially within the crotch region. The front chassis and front waistband regions may comprise a plurality of elastomeric strands disposed between a first material and a material and are bonded together by a plurality of discrete bonds, at least some of which entrap the strands. The strands of the front chassis region are spaced apart a first distance, while the strands of the front waistband region are spaced apart a second distance, with the second distance being less than the first distance.

Abstract: The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine-based inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.

Abstract: A urine collection device includes a collection member extending from a proximal end to a distal end. The proximal end includes an opening that provides access to an internal cavity of the collection member. The internal cavity includes a first chamber in fluid communication with a second chamber. The urine collection device includes a spacer in the second chamber, a first attachment member extending from a bottom wall of the collection member at the proximal end, a second attachment member extending from a top wall of the collection member at the proximal end, and an outlet for egressing urine from the internal cavity of the collection member. The first attachment member defines an aperture. The collection member is suitable to (i) direct urine from the first chamber to the second chamber and (ii) direct the urine in the second chamber distally toward the outlet.

Abstract: An absorbent article having a liquid pervious topsheet wherein at least a portion of the topsheet has been treated to become hydrophobic; a backsheet joined to said topsheet; an absorbent core disposed between said topsheet and said backsheet, said absorbent core having an inner surface oriented toward the skin of the wearer when said absorbent article is being worn and an outer surface oriented toward the garment of the wearer when said absorbent article is being worn; and a surfactant applied to at least a portion of said outer surface of said topsheet wherein the topsheet has been treated hydrophobic and wherein the hydrophilic surfactant is added to the areas treated hydrophobic.

Abstract: Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.

Abstract: A barrier for use in negative pressure wound therapy can include a base layer and surface structures. The barrier can be used to reduce or prevent tissue ingrowth. A method of using a negative pressure wound therapy system can include positioning a perforated barrier in a wound. After positioning the perforated barrier in the wound, positioning a pad in the wound on top of the perforated barrier, positioning a seal on top of the wound to at least partially seal the perforated barrier and the foam in the wound, and applying negative pressure wound therapy to the wound.

Abstract: The various aspects present inventions provide various crystalline forms of (S)-(?)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

Abstract: Disclosed embodiments relate to apparatuses and methods for wound treatment. In certain embodiments, a negative pressure wound therapy apparatus can include a spacer layer with an upper portion and a lower portion. The spacer layer can be configured to be wrapped around at least one edge of the absorbent layer with the upper portion of the spacer layer being above the absorbent layer and the lower portion of the spacer layer being below the absorbent layer. In some embodiments, a negative pressure wound therapy apparatus can include a first and second spacer layer and an absorbent layer. The first spacer layer can be positioned below the absorbent layer and the first spacer layer can have a perimeter larger than a perimeter of the absorbent layer. The second spacer layer can be positioned above the absorbent layer. The second spacer layer can have a perimeter larger than the perimeter of the absorbent layer.

Abstract: A negative pressure assembly includes a drape, a sealing element, a reactor, a valve and a mechanical pump assembly. The drape and the sealing element, when applied to the skin, cooperate to define an enclosed volume. The reactor is located so as to be in fluid communication with the enclosed volume when the drape is covering the dressing site. The reactor reacts with a selected gas found in air to consume the selected gas. The valve has a first operating state in which gas is drawn from the enclosed volume through the valve. The mechanical pump assembly includes a pump chamber fluidly connectable to the enclosed volume through the valve when the valve is in the first operating state. The mechanical pump is configured to fluidly connect with the enclosed volume and draw air from the enclosed volume into the pump chamber.